Evidence map›Paper›PMID 42019090›Full record

Trial reportEBioMedicine2026

Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial.

Liem T Nguyen, Kien T Nguyen, Lan T M Dao, Van T Hoang, Trang T K Phan, Nhung T H Dinh, Ha T Nguyen, Anh T P Nguyen, Thuy T N Nguyen, Thanh T K Ho and 1 more

Erratum issuedAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Liem T NguyenVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam; Ha Noi Medical University, 1 Ton That Tung, Dong Da District, Hanoi, Vietnam. Electronic address: liem.nt@vinuni.edu.vn.
Kien T NguyenVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam.
Lan T M DaoVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam.
Van T HoangVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam.
Trang T K PhanVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam.
Nhung T H DinhVinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Vinhomes Ocean Park, Gia Lam District, Hanoi, Vietnam.
Ha T NguyenVinmec HealthCare System, 458 Minh Khai Street, Hai Ba Trung District, Hanoi, Vietnam.
Anh T P NguyenVinmec HealthCare System, 458 Minh Khai Street, Hai Ba Trung District, Hanoi, Vietnam.
Thuy T N NguyenHa Noi Medical University, 1 Ton That Tung, Dong Da District, Hanoi, Vietnam.
Thanh T K HoHa Noi Medical University, 1 Ton That Tung, Dong Da District, Hanoi, Vietnam.
Quyet M NguyenVietnam National Children's Hospital, 18/879 La Thanh Street, Lang Ward, Hanoi, Vietnam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFrailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults.

methodsA phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10

findingsNo UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously. At nine months, the UC-MSC group showed higher SPPB scores than controls (least-squares mean difference 1.1 points, 95% CI: 0.6-1.6).

interpretationIn this study, UC-MSC infusion was associated with no safety concerns and was associated with higher SPPB scores than in the control group. These findings provide the necessary rationale and foundation for larger, double-blind, multicentre phase 3 trials.

fundingVingroup Joint Stock Company, grant ISC.21.11.

Indexed as

FrailtyMesenchymal Stem CellsMesenchymal Stem Cell TransplantationUmbilical CordAgedAged, 80 and overFemaleFrail ElderlyHumansMaleMiddle AgedQuality of LifeTransplantation, HomologousTreatment OutcomeCell therapyFrailtyRandomised controlled clinical trialUC-MSC

Identifiers

PMID42019090
PMCPMC13123506

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.